AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/04/21
AC Immune Presents Full Phase 1b Results on Anti-Abeta Vaccine and Discusses its First-in-Class Diagnostic for Parkinson's Disease at AAIC 2021GlobeNewsWire • 07/29/21
Earnings Preview: AC Immune (ACIU) Q2 Earnings Expected to DeclineZacks Investment Research • 07/28/21
AC Immune Secures Funding From BioNTech Investors, Buys Parkinson's Vaccine CandidateBenzinga • 07/27/21
AC Immune acquires AFFiRiS' Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseasesGlobeNewsWire • 07/27/21
AC Immune Announces Strategic Acquisition of Industry-leading Parkinson's Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbHGlobeNewsWire • 07/27/21
AC Immune Stock Jumps After Alzheimer's Disease Vaccine Candidate Confirms Favorable Safety, Tolerability ProfileBenzinga • 06/02/21
AC Immune Provides Update on Alzheimer's Disease Vaccine Candidates Targeting Pathological Amyloid-BetaGlobeNewsWire • 06/02/21
AC Immune to Highlight First-in-Class Alzheimer's Disease Vaccine Programs at Upcoming Investor ConferencesGlobeNewsWire • 05/20/21
AC Immune Reports First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 04/28/21
AC Immune Appoints Experienced Biotech and Investment Executive Dr. Alan Colowick to Board of DirectorsGlobeNewsWire • 03/31/21
AC Immune Hosts Investor Webinar Highlighting the Power of its Morphomer™ Platform to Enable Precision Medicine for Neurodegenerative DiseaseGlobeNewsWire • 03/31/21
AC Immune to Host Webinar Highlighting its Innovative Morphomer™ Technology Platform and PipelineGlobeNewsWire • 03/26/21
AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D OutlookGlobeNewsWire • 03/23/21
AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative DiseasesGlobeNewsWire • 03/09/21